9 Reasons Menopause-Related Depression Is Systematically Misdiagnosed and Mistreated in Primary Care
The thing that still stings is how quickly 'you're just depressed' was offered as a full explanation — as if that settled it. Nobody asked whether anything had changed hormonally. Nobody mentioned perimenopause. If you've been handed an antidepressant and something still feels off, you're not imagining it, and you're not alone in having been underserved at exactly the moment you needed someone to look harder.
Learn more about Rose →Primary care training in perimenopause is minimal and often outdated
Most GP training programs dedicate very little time to the hormonal changes of perimenopause, and much of what is taught reflects pre-2002 fears rooted in a now-discredited reading of the Women's Health Initiative study. This leaves many clinicians poorly equipped to recognize that a 47-year-old with new-onset low mood, poor sleep, and irritability may be experiencing estrogen-withdrawal effects rather than a primary mood disorder. The gap between what practitioners know and what the evidence now shows is wide enough that patients routinely fall through it.
The diagnostic criteria for depression don't distinguish hormonal cause from psychiatric cause
Standard depression screening tools like the PHQ-9 measure symptom severity — they don't ask why the symptoms are happening or whether they correlate with a hormonal transition. A perimenopausal woman with disrupted sleep from night sweats, low energy from estrogen fluctuation, and anhedonia driven by progesterone decline will score just as high on that scale as someone with a primary depressive disorder. Fitting the criteria for depression doesn't mean antidepressants are the right first treatment — it means a differential diagnosis is needed.
Estrogen's direct role in serotonin regulation is rarely part of the clinical conversation
Estradiol directly influences serotonin synthesis, serotonin receptor sensitivity, and the reuptake of serotonin in the brain — the same systems that SSRIs target pharmacologically. When estrogen drops sharply or fluctuates erratically during perimenopause, serotonin signalling is genuinely disrupted, which produces symptoms that are clinically indistinguishable from major depression. Treating this with an antidepressant addresses the downstream symptom without touching the upstream hormonal cause, which is why so many women report that antidepressants 'took the edge off' but never made them feel like themselves again.
Irregular periods are rarely flagged as a diagnostic clue in a mental health consultation
A woman presenting with depression in her mid-40s who also mentions irregular periods is handing her clinician a significant diagnostic clue — but those two pieces of information are rarely connected in a short primary care appointment. Menstrual irregularity is one of the earliest and most reliable markers of perimenopause, and its co-occurrence with mood changes should prompt hormonal evaluation as part of the differential. Instead, each symptom tends to be treated in isolation: the mood gets an antidepressant, the periods get 'watchful waiting.'
FSH and estradiol testing is often skipped because results can be misleadingly 'normal'
Clinicians sometimes avoid hormonal blood tests in perimenopause because they know the results fluctuate day to day and don't give a clean picture — which is a reasonable concern, but it can't be the end of the investigation. The problem is that 'we can't rely on blood tests' has been operationalised into 'so we won't test at all,' leaving women with no hormonal data when a clinical assessment of symptoms and cycle history could still point clearly toward a perimenopausal picture. A single normal FSH result does not rule out perimenopause, and it certainly doesn't rule out estrogen as the driver of mood symptoms.
Sleep disruption from vasomotor symptoms is fuelling mood disorders that get labelled as primary depression
Night sweats and sleep-disrupting hot flashes are among the most underappreciated contributors to perimenopausal depression, because chronic sleep fragmentation alone is sufficient to produce symptoms that meet the clinical threshold for a depressive episode. When a woman tells her doctor she's waking two or three times a night drenched in sweat and then feels hopeless and exhausted through the day, the causal chain is visible — but it's frequently overlooked in favour of a diagnosis that fits neatly on a prescription. Treating the vasomotor symptoms, often with estrogen therapy, frequently resolves the mood symptoms without any antidepressant at all.
Progesterone's anxiolytic effects are almost never discussed in the depression conversation
Natural progesterone is metabolised in the brain into allopregnanolone, a potent positive modulator of GABA receptors that produces calming, anxiolytic effects — essentially the body's own mild tranquiliser. As progesterone drops in perimenopause, this natural buffer disappears, and many women experience a new and unfamiliar level of anxiety, agitation, and emotional volatility that they've never had before. This is biology, not psychology, and yet it is almost never offered as an explanation to a woman who comes in describing anxiety and low mood for the first time at 49.
Women are more likely to be offered psychotherapy or antidepressants than hormonal treatment for mood symptoms
Multiple studies have documented a persistent pattern in which women's somatic and mood symptoms are more readily attributed to psychological causes than equivalent symptoms in men, a phenomenon researchers have termed 'gender bias in diagnosis.' In the context of perimenopause, this manifests as a tendency to reach for antidepressants or CBT referrals before considering that a woman's brain chemistry has literally changed because her hormone environment has changed. This is not about dismissing the value of therapy — it's about the sequencing, and the fact that hormonal evaluation is routinely skipped as a first step.
The evidence that estrogen outperforms antidepressants for perimenopausal depression is being ignored in practice
A landmark randomised controlled trial published in JAMA Psychiatry found that transdermal estradiol was significantly more effective than placebo in reducing depressive symptoms in perimenopausal women — and subsequent research has consistently supported estrogen as a first-line mood intervention for women in the menopause transition, particularly those without a prior history of depression. This evidence has not meaningfully changed what happens in a typical GP appointment, where antidepressants remain the default and HRT is rarely offered as a treatment for mood. The gap between what the research says and what women actually receive in the consulting room remains one of the most consequential failures in women's healthcare.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.